Thu. 2 May 2024, 4:00pm ET
Benzinga
Earnings, Earnings Misses, News
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.77) by 14.69 percent. The company reported quarterly sales of $108.833 million which missed the analyst consensus estimate of $116.009 million by 6.19 percent. This is a 8.30 percent increase over sales of $100.496 million the same period last year.